Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.34 |
| ▸ | ABAT | P80404 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL500576 | 1.00 | FFAR3 (0.35) | FFAR3GRIK1ABATEPHX2PPARG | |
| Hydrochloric Acid SCHEMBL27563634 | 0.98 | GRIK1 (0.33) | FFAR3GRIK1ABATEPHX2PPARG | |
| SCHEMBL11233789 | 0.79 | EPHX2 (0.32) | GRIK1EPHX2PPARG | |
| SCHEMBL14723746 | 0.78 | GRIK1 (0.53) | FFAR3GRIK1EPHX2PPARGGRIK2 | |
| SCHEMBL9418732 | 0.78 | GRIK1 (0.53) | FFAR3GRIK1EPHX2PPARGGRIK2 | |
| SCHEMBL8828770 | 0.77 | ABAT (0.34) | FFAR3GRIK1ABAT | |
| SCHEMBL5359965 | 0.77 | THRB (0.34) | GRIK1 | |
| SCHEMBL2418566 | 0.76 | FFAR3 (0.35) | FFAR3GRIK1GRIK2KDM4ETSHR | |
| SCHEMBL2418563 | 0.76 | FFAR3 (0.35) | FFAR3GRIK1GRIK2KDM4ETSHR | |
| SCHEMBL8152582 | 0.76 | ALDH1A1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1044991-B1 | Process of preparing curable compositions and compositions therefrom | ROHM & HAAS (US) | 2004-02-11 | — | — | EP | claimed |
| US-20240043593-A1 | Fluorine-Containing Polymer | CENTRAL GLASS COMPANY, LIMITED (JP) | 2024-02-08 | — | — | US | disclosed |
| WO-2022124183-A1 | FLUORINE-CONTAINING POLYMER | セントラル硝子株式会社 | 2022-06-16 | — | — | WO | disclosed |
| EP-3215476-B1 | METHOD FOR PREPARATION OF FLUORO, CHLORO AND FLUOROCHLORO ALKYLATED COMPOUNDS BY HOMOGENEOUS CATALYSIS | LONZA AG (CH) | 2018-02-28 | — | — | EP | disclosed |
| US-9809596-B1 | Method for preparation of fluoro, chloro and fluorochloro alkylated compounds by homogeneous catalysis | LONZA LTD. (CH) | 2017-11-07 | — | — | US | disclosed |
| EP-3215476-A1 | METHOD FOR PREPARATION OF FLUORO, CHLORO AND FLUOROCHLORO ALKYLATED COMPOUNDS BY HOMOGENEOUS CATALYSIS | Lonza Ltd (CH) | 2017-09-13 | — | — | EP | disclosed |
| US-9599758-B2 | Optical reflective film and optical reflector using the same | Konica Minolta, Inc. (JP) | 2017-03-21 | — | — | US | disclosed |
| WO-2016071425-A1 | METHOD FOR PREPARATION OF FLUORO, CHLORO AND FLUOROCHLORO ALKYLATED COMPOUNDS BY HOMOGENEOUS CATALYSIS | LONZA LTD (CH) | 2016-05-12 | — | — | WO | disclosed |
| US-20150285974-A1 | OPTICAL REFLECTIVE FILM AND OPTICAL REFLECTOR USING THE SAME | Konica Minolta, Inc. (JP) | 2015-10-08 | — | — | US | disclosed |
| US-20150218144-A1 | SUBSTITUTED PHENYLCARBAMATE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-08-06 | — | — | US | disclosed |
| EP-1386662-A1 | Double metal cyanide catalysts for preparing polyether polyols | Bayer Aktiengesellschaft (DE) | 2004-02-04 | — | — | EP | disclosed |
| US-20040019019-A1 | Pyrrolo[1,2-b][1,2,4]oxadiazine diones useful as nitric oxide synthase inhibitors | PHARMACIA CORPORATION | 2004-01-29 | — | — | US | disclosed |
| US-6552052-B2 | (2S,3Z)-2-amino-5-(6,7,8,9-tetrahydro-3-oxo-3H,5H -(1,2,4)oxadiazolo(4,3-a)azepin-5-yl)-3-pentenoic acid, for example | MONSANTO/G.D. SEARLE | 2003-04-22 | — | — | US | disclosed |
| US-6489323-B1 | INHIBITING NO PRODUCTION FROM L-ARGININE, AS SEEN IN DISEASE STATES SUCH AS ARTHRITIS AND SYSTEMIC HYPOTENSION ASSOCIATED WITH SEPTIC AND/OR TOXIC SHOCK | G.D. SEARLE & CO. | 2002-12-03 | — | — | US | disclosed |
| US-20010044539-A1 | Heterobicyclic and tricyclic nitric oxide synthase inhibitors | HANSEN DONALD W (US) | 2001-11-22 | — | — | US | disclosed |
| EP-1086108-A1 | HETEROBICYCLIC AND TRICYCLIC NITRIC OXIDE SYNTHASE INHIBITORS | G.D. Searle & Co. (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999064426-A1 | HETEROBICYCLIC AND TRICYCLIC NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1999-12-16 | — | — | WO | disclosed |
| US-5629264-A | 2-aryl-5,6-dihydropyrimidinones and herbicidal use thereof | ROHM AND HAAS COMPANY (US) | 1997-05-13 | — | — | US | disclosed |
| EP-0733622-A1 | 2-Aryl-5,6-dihydropyrimidinones and herbicidal use thereof | ROHM AND HAAS COMPANY (US) | 1996-09-25 | — | — | EP | disclosed |
| EP-0021883-A2 | N-acyl-amino acid derivatives and pharmaceutical compositions containing them, intermediates and starting compounds | MERRELL TORAUDE ET COMPAGNIE (FR) | 1981-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218144-A1 | SUBSTITUTED PHENYLCARBAMATE COMPOUNDS | TRPA1, TRPV1, TRPV3 | FFAR3 58/4885GRIK1 213/4885ABAT 961/4885 |
| US-20010044539-A1 | Heterobicyclic and tricyclic nitric oxide synthase inhibitors | NOS1, NOS2, NOS3 | FFAR3 1855/4885GRIK1 1900/4885ABAT 137/4885 |
| US-20040019019-A1 | Pyrrolo[1,2-b][1,2,4]oxadiazine diones useful as nitric oxide synthase inhibitors | NOS1, NOS2, NOS3 | FFAR3 2006/4885GRIK1 1331/4885ABAT 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.